as 08-29-2025 12:33pm EST
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
Founded: | 1849 | Country: | United States |
Employees: | N/A | City: | NEW YORK |
Market Cap: | 142.5B | IPO Year: | N/A |
Target Price: | $29.36 | AVG Volume (30 days): | 43.0M |
Analyst Decision: | Hold | Number of Analysts: | 12 |
Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
EPS: | 1.89 | EPS Growth: | N/A |
52 Week Low/High: | $20.91 - $30.43 | Next Earning Date: | 10-28-2025 |
Revenue: | $63,833,000,000 | Revenue Growth: | 13.53% |
Revenue Growth (this year): | 0.39% | Revenue Growth (next year): | -0.72% |
PFE Breaking Stock News: Dive into PFE Ticker-Specific Updates for Smart Investing
Motley Fool
15 hours ago
Motley Fool
18 hours ago
Zacks
2 days ago
Zacks
2 days ago
Insider Monkey
2 days ago
The Wall Street Journal
2 days ago
Zacks
3 days ago
Zacks
3 days ago
The information presented on this page, "PFE Pfizer Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.